A gene expression-based classifier for HER2-low breast cancer

A gene expression-based classifier for HER2-low breast cancer

Abstract In clinical trials evaluating antibody-conjugated drugs (ADCs), HER2-low breast cancer is defined through protein immunohistochemistry scoring (IHC) 1+ or 2+ without gene amplification. However, in daily practice, the accuracy of IHC is compromised by inter-observer variability. Herein, we...

Full description

Bibliographic Details
Main Authors:	Serena Di Cosimo, Sara Pizzamiglio, Chiara Maura Ciniselli, Valeria Duroni, Vera Cappelletti, Loris De Cecco, Cinzia De Marco, Marco Silvestri, Maria Carmen De Santis, Andrea Vingiani, Biagio Paolini, Rosaria Orlandi, Marilena Valeria Iorio, Giancarlo Pruneri, Paolo Verderio
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-02-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-024-52148-7

Similar Items

End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO
by: Serena Di Cosimo, et al.
Published: (2023-01-01)

Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer
by: Marco Silvestri, et al.
Published: (2022-01-01)

Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended
by: Marta Giussani, et al.
Published: (2021-08-01)

Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world
by: Serena Di Cosimo, et al.
Published: (2022-09-01)

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
by: Ilona Rybinska, et al.
Published: (2020-02-01)

What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
by: Sara Pizzamiglio, et al.
Published: (2022-01-01)

A combination of extracellular matrix‐ and interferon‐associated signatures identifies high‐grade breast cancers with poor prognosis
by: Mara Lecchi, et al.
Published: (2021-05-01)

Correction: Effects of Warm Ischemic Time on Gene Expression Profiling in Colorectal Cancer Tissues and Normal Mucosa.
by: Valeria Musella, et al.
Published: (2013-01-01)

Data and performances evaluation of the SPIDIA-DNA Pan-European External Quality Assessment: 2nd SPIDIA-DNA laboratory report
by: Francesca Malentacchi, et al.
Published: (2016-03-01)

Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors
by: Emanuela Minna, et al.
Published: (2023-10-01)

Alterations in Plasma Lipid Profiles Associated with Melanoma and Therapy Resistance
by: Michele Dei Cas, et al.
Published: (2024-01-01)

Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma
by: Marco Silvestri, et al.
Published: (2023-04-01)

SARS-CoV-2 Serology Monitoring of a Cancer Center Staff in the Pandemic Most Infected Italian Region
by: Chiara Maura Ciniselli, et al.
Published: (2021-03-01)

Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy
by: Serena Di Cosimo, et al.
Published: (2019-11-01)

Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients
by: Marco Silvestri, et al.
Published: (2021-03-01)

3Rs Principle and Legislative Decrees to Achieve High Standard of Animal Research
by: Paolo Verderio, et al.
Published: (2023-01-01)

Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
by: Emma Zattarin, et al.
Published: (2020-12-01)

Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation
by: Sandra Romero-Cordoba, et al.
Published: (2019-06-01)

Multiparametric analysis of cell-free DNA in melanoma patients.
by: Francesca Salvianti, et al.
Published: (2012-01-01)

Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group
by: Luca Licata, et al.
Published: (2023-03-01)

Biomarkers for monitoring pre-analytical quality variation of mRNA in blood samples.
by: Hui Zhang, et al.
Published: (2014-01-01)

SPIDIA-RNA: second external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses.
by: Francesca Malentacchi, et al.
Published: (2014-01-01)

FCI: an R-based algorithm for evaluating uncertainty of absolute real-time PCR quantification
by: Gallo Fabio, et al.
Published: (2008-01-01)

Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer
by: Carolina Reduzzi, et al.
Published: (2021-05-01)

Long Non-Coding RNAs: Role in Testicular Cancers
by: Chiara Bresesti, et al.
Published: (2021-03-01)

Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation.
by: Loris De Cecco, et al.
Published: (2013-01-01)

Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma
by: Emanuela Minna, et al.
Published: (2020-01-01)

Vaccine Hesitancy
by: Valeria de Santis
Published: (2022-06-01)

COVID-19 Vaccination in Health Care Workers in Italy: A Literature Review and a Report from a Comprehensive Cancer Center
by: Chiara Maura Ciniselli, et al.
Published: (2022-05-01)

Noble Metals and Soft Bio-Inspired Nanoparticles in Retinal Diseases Treatment: A Perspective
by: Valeria De Matteis, et al.
Published: (2020-03-01)

Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
by: Francesca Ligorio, et al.
Published: (2021-04-01)

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
by: Lorenzo Ferrando, et al.
Published: (2023-01-01)

Monitoring of Animal Feed Contamination by Mycotoxins: Results of Five Years of Official Control by an Accredited Italian Laboratory
by: Cinzia Franchino, et al.
Published: (2024-01-01)

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
by: Jacopo Azzollini, et al.
Published: (2022-04-01)

Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer
by: Jacopo Azzollini, et al.
Published: (2019-01-01)

Insights on the bacterial composition of Parmigiano Reggiano Natural Whey Starter by a culture-dependent and 16S rRNA metabarcoding portrait
by: Laura Sola, et al.
Published: (2022-10-01)

Effects of Dried Blood Spot Storage on Lipidomic Analysis
by: Cinzia Di Marino, et al.
Published: (2018-02-01)

Disorders of Puberty in Severely Neurologically Impaired Children: Is Delayed Puberty an Underestimated Problem?
by: Valeria Calcaterra, et al.
Published: (2019-11-01)

Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients.
by: Valeria Musella, et al.
Published: (2015-01-01)

Green Plasmonic Nanoparticles and Bio-Inspired Stimuli-Responsive Vesicles in Cancer Therapy Application
by: Valeria De Matteis, et al.
Published: (2020-05-01)